Individualized Vocational and Educational Support and Training for Clinical High Risk for Psychosis (InVEST) (InVEST)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05114733 |
Recruitment Status :
Recruiting
First Posted : November 10, 2021
Last Update Posted : June 14, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to test the efficacy of InVEST (Individualized Vocational and Educational Support and Training) for CHR-P (clinical high risk for psychosis) to address specific role functioning difficulties associated with the CHR-P phase. Our specific goals are:
- Part 1: Preliminary open trial of InVEST (n = 8) to collect preliminary feasibility and acceptability data by providing the intervention, administering assessments, and collecting focus group and self-report feedback from open trial participants. The open trial phase will help to refine recruitment approaches and to modify the treatment manual as needed.
- Part 2: Preliminary randomized controlled trial of InVEST vs. Delayed InVEST (DI) to explore preliminary evidence of efficacy of InVEST vs. DI (n = 30). The investigators hope to gain understanding of the feasibility of InVEST and the study's assessment procedures, and to gain a preliminary understanding of the intervention's efficacy for functioning difficulties experienced by young people at CHR-P.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Clinical High Risk for Psychosis | Behavioral: InVEST | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 24 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | waitlist control design |
Masking: | Single (Outcomes Assessor) |
Masking Description: | part 1 is open label design. Next part is RCT waiting list control design. assessors will be unaware of whether the participant was in the waiting list condition or the active condition. |
Primary Purpose: | Treatment |
Official Title: | Individualized Vocational and Educational Support and Training for Clinical High Risk for Psychosis (InVEST) |
Actual Study Start Date : | March 15, 2022 |
Estimated Primary Completion Date : | June 2024 |
Estimated Study Completion Date : | June 2024 |

Arm | Intervention/treatment |
---|---|
Experimental: InVEST
4 month treatment condition
|
Behavioral: InVEST
Individualized vocational and educational support and training -- participant works with BA level school/ work coach for four months |
No Intervention: delayed invest
participants in delayed invest wait four months and are reassessed before taking part in the intervention
|
- Feasibility of intervention- recruitment rate [ Time Frame: baseline ]recruitment rates
- Feasibility of intervention -Client Satisfaction [ Time Frame: 4 months ]Attkisson Client Satisfaction Questionnaire is a seven item scale measuring an individual's personal experience with a service (range 7-28 with higher scores indicating greater level of satisfaction)
- Feasibility of intervention- drop out [ Time Frame: 4 months ]drop outs
- Role functioning [ Time Frame: change from baseline to 4 months and baseline to 8 months ]The global functioning role scale is a 10 point scale that rates school or work functioning. The scale ranges from 1-10, with 10 indicating the highest level of functioning.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion:
- age 12-18,
- can speak English,
- meet broad CHR-P criteria based on the Structured Interview for Psychosis Risk Syndromes (SIPS),
- shows at least mild role functioning impairment on the Global Functioning-Role scale (GF:R),
- parent is willing to provide permission (and client is willing to assent) for invest coaches to communicate with treatment providers.
Exclusion:
- Previously met diagnostic criteria for full psychosis on the Structured Interview for Psychosis Risk Syndromes.
- Does not meet inclusion criteria listed above.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05114733
Contact: Michelle Friedman-Yakoobian | 617-754-1210 | mfriedm3@bidmc.harvard.edu | |
Contact: Michelle West | MICHELLE.WEST@CUANSCHUTZ.EDU |
United States, Massachusetts | |
Beth Israel Deaconess Medical Center/ Massachusetts Mental Health Center | Recruiting |
Boston, Massachusetts, United States, 02115 |
Principal Investigator: | Michelle Friedman-Yakoobian, PHD | Department of Psychiatry at BIDMC - a major teaching hospital of Harvard Medical School |
Other Publications:
Responsible Party: | Michelle Friedman-Yakobian, Assistant Professor, Beth Israel Deaconess Medical Center |
ClinicalTrials.gov Identifier: | NCT05114733 |
Other Study ID Numbers: |
2021P000689 |
First Posted: | November 10, 2021 Key Record Dates |
Last Update Posted: | June 14, 2022 |
Last Verified: | June 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
clinical high risk for psychosis psychosis risk syndrome school functioning intervention |
Psychotic Disorders Mental Disorders Schizophrenia Spectrum and Other Psychotic Disorders |